Patents by Inventor Nicolas Gilles

Nicolas Gilles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VASOPRESSIN-2 RECEPTOR ANTAGONIST PEPTIDES AND USES THEREOF
    Publication number: 20230234994
    Abstract: A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX1CNLPVKPGPCX2GFFSAFYYSQKX3NKCHSFTYGGCAGNANRFSTX4EKCRRTC X5X6, wherein, X1 is the amino acid residue F or G, X2 is any amino acid residue, except a basic amino acid residue, X3 is the amino acid residue T or D, X4 is the amino acid residue I, L, or E, (i) X5 is V and X6 is G or (ii) X5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.
    Type: Application
    Filed: June 23, 2021
    Publication date: July 27, 2023
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Nicolas GILLES, Justyna CIOLEK, Laura DROCTOVE, Bernard MAILLERE, Herve NOZACH
  • Peptide antagonists of the vasopressin-2 receptor
    Patent number: 9631001
    Abstract: The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 25, 2017
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITY OF REGENSBURG, UNIVERSITY DE LIEGE
    Inventors: Nicolas Gilles, Denis Servent, Loïc Quinton, Helen Reinfrank, Ralph Witzgall, Bernard Mouillac, Christiane Mendre
  • PEPTIDE ANTAGONISTS OF THE VASOPRESSIN-2 RECEPTOR
    Publication number: 20150252086
    Abstract: The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.
    Type: Application
    Filed: September 17, 2013
    Publication date: September 10, 2015
    Inventors: Nicolas Gilles, Denis Servent, Loïc Quinton, Helen Reinfrank, Ralph Witzgall, Bernard Mouillac, Christiane Mendre
  • PEPTIDES WITH PROPERTIES OF AN ALLOSTERIC ANTAGONIST SELECTIVE FOR THE ALPHA 1A ADRENERGIC RECEPTOR AND USES THEREOF
    Publication number: 20110117017
    Abstract: Peptides characterized by: a) a sequence selected from the group consisting of the sequence SEQ ID NO: 2, and the derived variants having at least 70% identity or 80% similarity with the entire sequence SEQ ID NO: 2, b) a three-finger structure including eight cysteine residues linked by four disulfide bridges, respectively between the first and the third cysteine, the second and the fourth cysteine, the fifth and the sixth cysteine, and the seventh and the eighth cysteine, and c) an activity of an allosteric antagonist selective for the alpha 1a adrenergic receptor, and therapeutic and pharmacological uses thereof.
    Type: Application
    Filed: February 23, 2007
    Publication date: May 19, 2011
    Inventors: Nicolas Gilles, André Menez, Renée Menez, Christopher Menez, Cécile Berlioz